ARMP — Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: AMEX
- Employees: 60
- Website: https://www.armatapharma.com
Latest SEC filings for ARMP
- 8-K — 2026-08-12
- 10-Q — 2026-08-12
- 8-K — 2026-07-20
- 8-K — 2026-07-20
- 8-K — 2026-07-13
- 8-K/A — 2026-06-24
- 8-K — 2026-06-23
- 8-K — 2026-06-16
- 10-Q — 2026-05-13
- 8-K — 2026-05-13
Latest ARMP news
- — Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States (prnewswire.com)
Educational tool only — not investment advice.